Therapeuticsmd, Inc. · NASDAQ:TXMD
Therapeuticsmd — Q1 2022 Earnings Presentation
13 slides from Therapeuticsmd's earnings presentation, May 16, 2022
Slide 1: Building the Premier Women's Health Company Q1 2022 Earnings
Building the Premier Women’s Health Company Q1 2022 Earnings May 16, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, th
Slide 3: Hugh O'Dowd, CEO
TherapeuticsMD” 1 1 For Her: For Life. Hugh O’Dowd CEO
Slide 4: Q1 2022 Financial Overview
TherapeuticsMD” 1 1 . 1 For Her: For Life. Q1 2022 Financial Overview
Slide 5: Quarterly Revenue Trends and Q1-22 Highlights
$18.7 Quarterly Revenue (YoY) Quarterly Revenue Trends Millions Q1-22 Highlights Total net revenue decreased 3% in Q1-22 vs Q1-21, but increased 4% vs Q4-21 Total net product revenue decreased 4% in Q1-22 vs Q1-21, but increased 1% vs Q4-21 ANNOVERA net revenue decreased 3% in Q1-22 vs Q1-21 and was
Slide 6: Financial Results: Comparison Q1 2022 to Q1 2021 and Q4 2021
Financial Results: Comparison Q1 2022 to Q1 2022 to Q4 2021 In April, certain proceeds from the vitaCare divestiture were used to paydown the debt; April 30th debt balance was $89M. Gross margin of 75% in Q1-22 relatively consistent Q1-21 and Q4-21. Operating expenses in Q1-22 decreased $3.8M from Q
Slide 7: Q1 2022 Commercial Overview
7 Q1 2022 Commercial Overview
Slide 8: Call Activity Highlights
Call Activity Highlights 9.2 calls per day 6,271 targets reached (87%) 10,868 calls to targets (84%) *Source: Veeva; reflects Mar22 call activity, excluding vacancies and new hires in training 8
Slide 9: Available ANNOVERA vs. Prescriptions
Available ANNOVERA vs. Prescriptions 9 Cumulative Shipments to Prescriptions Filled
Slide 10: ANNOVERA Quarterly TRx
ANNOVERA Quarterly TRx +27% vs. Q121 Source: Symphony Metys – December 2021 Performance 10
Slide 11: ANNOVERA Prescribers: Launch to Date
ANNOVERA Prescribers: Launch to Date Source: Symphony Metys – April 2022; 5 prescribers in Q319 New prescribers defined as not having written Annovera in prior periods 11
Slide 12: IMVEXXY Monthly TRx
IMVEXXY Monthly TRx Source: Symphony Metys – April 2022 12
Slide 13: BIJUVA Quarterly TRx
BIJUVA Quarterly TRx Source: Symphony Metys – April 2022 13